Marrick L Kukin, MD Email Marrick Kukin
- PROFESSOR | Medicine, Cardiology
- Internal Medicine
- Cardiovascular Disease
- Hospital Affiliations
- The Mount Sinai Hospital
- Mount Sinai St. Luke's and Mount Sinai West
Congestive heart failure
Am Board of Internal Medicine (Int Med)
Am Board of Internal Medicine (Sub: Cardv Disease)
Dr. Marrick L. Kukin is the Director of the Heart Failure Program at Mount Sinai St. Luke’s-Roosevelt Hospitals in New York City and is Professor of Medicine at the Icahn School of Medicine at Mount Sinai, New York, NY. Dr. Kukin’s areas of research have included beta blockade and other neurohormonal antagonists in congestive heart failure, and the use of inotropic agents in heart failure. Among other honors, he received the Denber Award for Excellence in Cardiovascular Research from the Mount Sinai School of Medicine and was voted the Michael Lesch Teacher of the Year by the cardiology fellows in 2008. His articles have been published in various scientific journals, including American Journal of Cardiology, Circulation, Chest, Journal of the American College of Cardiology, and New England Journal of Medicine. Dr. Kukin has recently been appointed as a co-editor of Progress in Cardiovascular Diseases. He is an associate editor of Congestive Heart Failure and a reviewer for American Heart Journal, Circulation, European Journal of Heart Failure and Journal of the American College of Cardiology. He edited a book entitled “Oxidative Stress and Cardiac Failure,” (Futura/ Blackwell Publishing, Armonk NY 2003). He is a fellow of the American Heart Association (FAHA), and is a fellow of the American College of Cardiology (FACC). He is Co-Founder of the New York Heart Failure Club where he continues to serve as Co-Chairman of the Program Committee. He has served on the Program Committee and the Corporate Affairs Committee of the Heart Failure Society of America. He serves or has served on several Steering Committees and End-Point Adjudication Committees for national and international heart failure trials. Dr. Kukin received his undergraduate degree from Princeton University and his MD degree from the University of Pittsburgh in Pittsburgh Pennsylvania. He completed his residency in medicine and fellowship in cardiovascular disease at the Mount Sinai School of Medicine in New York City.
American Board of Internal Medicine
- Cardiovascular Disease
MD, University of Pittsburgh
, Mount Sinai Medical Center
, Mount Sinai Medical Center
, Mount Sinai Medical Center
Residency, Internal Medicine
Mount Sinai Hospital
Mount Sinai Hospital
1978 Princeton University Magna Cum Laude John Robinson Memorial Prize Isidore and Helen Sacks Memorial Prize
1991- 1995 Mount Sinai School of Medicine Arthur Ross Scholar in Cardiovascular Medicine
1990 Mount Sinai School of Medicine Denber Award for Excellence in Cardiovascular Research
2008 Teacher of the Year -Cardiology St. Lukes Roosevelt Division of Cardiology
1979, 1980 University of Pittsburgh Medical Alumni Association Research Grants,
1988 Mount Sinai School of Medicine Association of the Attending Staff /Bella Trachtenberg Award for House Staff Excellence
Kukin M. Research with recombinant DNA: Potential risks, potential benefits, and ethical considerations. N Y State J Med 1978; 78:226-235..;.
Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. Journal of the American College of Cardiology 2006 Jan; 47(1).
Davis ME, Richards AM, Nicholls MG, Yandle TG, Frampton CM, Troughton RW. Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure. Circulation 2006 Feb; 113(7).
Khan MN, Jaïs P, Cummings J, Di Biase L, Sanders P, Martin DO, Kautzner J, Hao S, Themistoclakis S, Fanelli R, Potenza D, Massaro R, Wazni O, Schweikert R, Saliba W, Wang P, Al-Ahmad A, Beheiry S, Santarelli P, Starling RC, Dello Russo A, Pelargonio G, Brachmann J, Schibgilla V, Bonso A, Casella M, Raviele A, Haïssaguerre M, Natale A. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. The New England journal of medicine 2008 Oct; 359(17).
Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, Rumsfeld JS. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009 Mar; 301(9).
Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, Thakkar R, Padley RJ, Põder P, Kivikko M. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007 May; 297(17).
Jones RH, Velazquez EJ, Michler RE, Sopko G, Oh JK, O'Connor CM, Hill JA, Menicanti L, Sadowski Z, Desvigne-Nickens P, Rouleau JL, Lee KL. Coronary bypass surgery with or without surgical ventricular reconstruction. The New England journal of medicine 2009 Apr; 360(17).
Giamouzis G, Butler J, Starling RC, Karayannis G, Nastas J, Parisis C, Rovithis D, Economou D, Savvatis K, Kirlidis T, Tsaknakis T, Skoularigis J, Westermann D, Tschöpe C, Triposkiadis F. Impact of dopamine infusion on renal function in hospitalized heart failure patients: results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial. Journal of cardiac failure 2010 Dec; 16(12).
Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010 Sep; 376(9744).
Abdel-Qadir HM, Tu JV, Yun L, Austin PC, Newton GE, Lee DS. Diuretic dose and long-term outcomes in elderly patients with heart failure after hospitalization. American heart journal 2010 Aug; 160(2).
Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms. The New England journal of medicine 2011 Jan; 364(1).
Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, LeWinter MM, Deswal A, Rouleau JL, Ofili EO, Anstrom KJ, Hernandez AF, McNulty SE, Velazquez EJ, Kfoury AG, Chen HH, Givertz MM, Semigran MJ, Bart BA, Mascette AM, Braunwald E, O'Connor CM. Diuretic strategies in patients with acute decompensated heart failure. The New England journal of medicine 2011 Mar; 364(9).
O'Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, Heizer GM, Komajda M, Massie BM, McMurray JJ, Nieminen MS, Reist CJ, Rouleau JL, Swedberg K, Adams KF, Anker SD, Atar D, Battler A, Botero R, Bohidar NR, Butler J, Clausell N, Corbalán R, Costanzo MR, Dahlstrom U, Deckelbaum LI, Diaz R, Dunlap ME, Ezekowitz JA, Feldman D, Felker GM, Fonarow GC, Gennevois D, Gottlieb SS, Hill JA, Hollander JE, Howlett JG, Hudson MP, Kociol RD, Krum H, Laucevicius A, Levy WC, Méndez GF, Metra M, Mittal S, Oh BH, Pereira NL, Ponikowski P, Tang WH, Wilson WH, Tanomsup S, Teerlink JR, Triposkiadis F, Troughton RW, Voors AA, Whellan DJ, Zannad F, Califf RM. Effect of nesiritide in patients with acute decompensated heart failure. The New England journal of medicine 2011 Jul; 365(1).
Ganesan AN, Brooks AG, Roberts-Thomson KC, Lau DH, Kalman JM, Sanders P. Role of AV nodal ablation in cardiac resynchronization in patients with coexistent atrial fibrillation and heart failure a systematic review. Journal of the American College of Cardiology 2012 Feb; 59(8).
Barsheshet A, Wang PJ, Moss AJ, Solomon SD, Al-Ahmad A, McNitt S, Foster E, Huang DT, Klein HU, Zareba W, Eldar M, Goldenberg I. Reverse remodeling and the risk of ventricular tachyarrhythmias in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy). Journal of the American College of Cardiology 2011 Jun; 57(24).
Bayes-Genis A, de Antonio M, Vila J, Peñafiel J, Galán A, Barallat J, Zamora E, Urrutia A, Lupón J. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3. Journal of the American College of Cardiology 2014 Jan; 63(2).
Castagno D, Skali H, Takeuchi M, Swedberg K, Yusuf S, Granger CB, Michelson EL, Pfeffer MA, McMurray JJ, Solomon SD. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. Journal of the American College of Cardiology 2012 May; 59(20).
Kukin M. Tay-Sachs and the abortion controversy. J of Religion and Health 1981; 20:224-242..;.
Goldman M, Packer M, Horowitz S, Meller J, Patterson R, Kukin M, Teichholz LE, Gorlin R. Relation between exercise-induced changes in ejection fraction and systolic loading conditions at rest in aortic regurgitation. J Am Coll Cardiol 1984; 3:924-929..;.
Packer M, Lee WH, Kessler PD, Gottlieb SS, Bernstein JL, Kukin ML. Role of neurohormonal mechanisms in determining survival in patients with severe chronic heart failure. Circulation 1987; 75 (suppl IV):80-92..;.
Gottlieb SS, Kukin ML, Medina N, Yushak M, Packer M. Adverse hemodynamic and clinical effects of encainide in severe chronic heart failure. Ann Intern Med 1989; 110:505-509.;.
Gottlieb SS, Kukin ML, Ahern D, Packer M. Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. J Am Coll Cardiol 1989; 13:1534-1539..;.
Packer M, Kukin ML, Neuberg GW, Pinsky DJ, Penn J, Abittan MH. The current status of angiotensin converting enzyme inhibitors in the management of chronic heart failure. J Hypertension 1989; 7(Suppl 5): S33-S36. .;.
Gottlieb SS, Kukin ML, Medina N, Yushak M, Packer M. Comparative hemodynamic effects of procainamide, tocainide and encainide in chronic heart failure. Circulation 1990; 81:860-864..;.
Coplan NL, Shimony RY, Ioachim H, Wilentz JR, Posner D, Lipschitz A, Ruden RA, Sherrid MV, Gaetz H, Kukin ML, Packer M. Primary pulmonary hypertension in association with the acquired immunodeficiency syndrome. AJM 1990; 89:96-99. .;.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Kukin did not report having any of the following types of financial relationships with industry during 2017 and/or 2018: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.